Objectives: Postoperative infection and wound occurrence is a cause of significant morbidity after major lower extremity amputation (MLEA). We sought to determine the association between preoperative nasal methicillin-resistant Staphylococcus aureus (MRSA) colonization with postoperative wound infection and wound occurrence after MLEA.
Objectives: Postoperative infection and wound occurrence is a cause of significant morbidity after major lower extremity amputation (MLEA). We sought to determine the association between preoperative nasal methicillin-resistant Staphylococcus aureus (MRSA) colonization with postoperative wound infection and wound occurrence after MLEA.
Methods: The medical records of all patients undergoing MLEA from August 1, 2011 to November 1, 2013 at our institution were reviewed. Demographic data, hemoglobin A 1c concentration, albumin concentration, dialysis dependence, and the presence of nasal MRSA colonization and diabetes mellitus (DM) were recorded. The occurrence of open wound infections, noninfected wound occurrence, and overall nonprimary healing rates were determined.
Results: A total of 83 patients underwent 96 MLEA over a 27-month period. The rates of nonprimary healing, open infected wounds, and repeat operations were 40%, 22%, and 24%, respectively. Nasal MRSA colonization was present in 26% of patients. MRSA was the most common cause of postoperative wound infection, occurring in 75% of postoperative wound infections. On univariate analysis, MRSA colonization, hemoglobin A 1c >8 mmol/mol, DM, and dialysis dependence are associated with higher rates of nonprimary healing (P < .05), but only nasal MRSA colonization is associated with higher rates of postoperative wound infection (15% vs 45%, P < .01). On multivariate analysis, only MRSA colonization is associated with higher postoperative wound infection rates (P < .01), while hemoglobin A 1c >8 mmol/mol and dialysis dependence are associated with higher rates of nonprimary healing (P < .02).
Conclusions: Nasal MRSA colonization is associated with a higher rate of postoperative wound infection after MLEA. Further studies addressing the effect of eradicating MRSA colonization or extending perioperative antibiotic coverage on post-operative infection rates are warranted. Objectives: In 2009, the Society for Vascular Surgery (SVS) established objective performance goals (OPG) for critical limb ischemia (CLI) based on data from randomized controlled trials of lower extremity bypass (LEB). These OPG sought to establish a benchmark from which to compare future endovascular therapy against established LEB outcomes. However, the cohort used to develop the OPG excluded all patients requiring prosthetic conduit and those with end-stage renal disease (ESRD), limiting the generalizability of these recommendations. The goal of this study was to determine if the SVS OPG are applicable to the current population of patients undergoing LEB.
Methods: All patients who underwent infrainguinal LEB for CLI from 2010 to 2012 were identified. Patients were stratified into OPG eligible and ineligible (NOPG) groups based on their demographic and operative characteristics. OPG eligible patients were further stratified into high and average risk. Outcomes included 30-day major adverse limb events (MALE), major adverse cardiac events (MACE), and 1-year amputation free survival (AFS).
Results: Eighty individual patients were identified. Demographics included age, 68 years; diabetes, 53%; dialysis, 10%; tissue loss, 55 (69%); previous infrainguinal procedure, 53 (66%); tibial distal target, 40 (50%); and prosthetic conduit, 38 (48%). Only 39 patients (49%) met OPG inclusion criteria, and 31(79%) of these stratified to high risk (18%: >80 years, 67% tissue loss, 56% tibial target, and 13% poor conduit). The 30-day MALE was 10% (2.5% OPG vs 17% NOPG; P ¼ .03). The MACE was 12.5%, with no difference between the cohorts (12% NOPG vs 13% OPG; P ¼ .93). The AFS for the entire cohort was 64% 6 5% and was significantly lower in the NOPG group (49% NOPG vs 80% OPG; P ¼ .005).
Conclusions: The SVS OPG for LEB are likely not generalizable to current practice because only 50% could be included in the OPG cohort, and of those, 80% were considered high risk. Despite this, the 30-day MALE and 1-year AFS rates were favorable in patients who met inclusion criteria for the OPG cohort.
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Outcomes Objectives: Endovascular intervention (EVI) is increasingly performed in patients with tissue loss (TL) and complex anatomy who would otherwise require primary amputation (PA). Guidelines for intervention/outcome analysis have been limited. We compared outcomes and costs associated with secondary amputation (SA) for nonhealing TL after EVI with PA in patients with critical limb ischemia (CLI) and TL.
Methods: All patients who presented to our health care system for surgical management of TL due to CLI from 2008 to 2010 were identified. Demographics, comorbidities, postoperative complications, insurer costs, followup hospitalizations, ambulatory/living status were analyzed (SPSS 21).
Results: There were 304 admissions: 263 (87%) EVI and 41 (13%) PA. Mean follow-up was 27 months (range, 0-101 months). SA was required in 80 (30%); mean time 6 months (range, 0-46 months). Independent predictors (likelihood ratio) for SA were contralateral amputation (4.1), gangrene (3.6), dialysis (3.1), TL not confined to the toes or heel alone (4.3), and preoperative angiogram showing less than two-vessel runoff (3.1). Comorbidities were comparable for SA and PA, including location of TL and presence of gangrene. Infection was more common in PA (87.8% vs 57.5%; P ¼ .001). Postoperative mortality was higher for PA (4.9% vs 0%; P ¼ .05), and 24-month survival was poorer (74% 6 8% vs 87% 6 4%; P ¼ .03). Hospitalizations (including amputation-related readmission), total hospital days, and insurer costs were higher for SA than PA (Table) . Thirty-nine (48%) SA underwent reintervention. There were no significant differences between SA and PA in maintenance of independent living (71% vs 72%; P ¼ .95) or ambulation (42% vs 58%; P ¼ .33).
Conclusions: Although ambulation and maintenance of independent living are comparable between SA and PA, EVI may be justified because of higher mortality in the PA group. However, multiple reinterventions will increase costs and incapacitation without improving outcome.
Author Disclosures: G. Cherr: Nothing to disclose; G. R. Curl: Nothing to disclose; H. H. Dosluoglu: Nothing to disclose; M. Dryjski: Nothing to disclose; L. Harris: Nothing to disclose; S. Noor: Nothing to disclose; M. O'Brien-Irr: Nothing to disclose. Objectives: Studies have shown regional differences in surgical practice though management of lower extremity arterial disease (PAD) has not been investigated. We used the Society for Vascular Surgery Vascular Quality Initiative (SVS VQI) to evaluate regional variation in PAD management.
Methods: SVS VQI was used to identify all infrainguinal bypass or endovascular intervention (PVI) from 2009 to 2012. Each of 14 quality groups was considered a region. Groups were deidentified. Indications and surgical approach were compared between groups. Groups with fewer than 100 cases were excluded on a per analysis basis.
Results (range, 115-10,251) . Substantial regional differences in patient comorbidities (eg, congestive heart failure, dialysis), indication for procedures (eg, infrapopliteal PVI for TASC D lesions), technical approach (eg. usage of prosthetic graft for infrapopliteal bypass graft) and use of evidence-based process measures (eg, chlorhexidine skin preparation for bypass) are demonstrated in the Table (P < .001 for all listed parameters).
Conclusions: This first investigation of a national clinical database demonstrates significant regional variation in PAD management. Future studies on the association of regional variation with risk-adjusted outcomes offer the opportunity for quality improvement through prospective identification of best practices.
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